Introduction: Despite the presence of many prognostic and predictive factors, overtreatment remains a major problem in patients with breast cancer. The aim of this study is to investigate the effects of CD74 and HLA-D...Introduction: Despite the presence of many prognostic and predictive factors, overtreatment remains a major problem in patients with breast cancer. The aim of this study is to investigate the effects of CD74 and HLA-DR expressions on the prognosis of patients who have had a mastectomy for the treatment of breast cancer. Materials and Methods: A retrospective search of medical records was carried out for patients who had surgery for breast cancer at the Department of General Surgery, Akdeniz University School of Medicine, between March 1984 and November 1999. Patients with regular follow-up and necessary data for the study (i.e. patients’ demographics, pathology results, and treatment characteristics) were included in the study. Paraffin blocks of tumor specimens were re-examined with immunohistochemical methods in March 2010 to determine the extent of CD74 and HLA-DR expression and the level of tumor infiltrating lymphocyte (TILs). Results: The mean age and the median duration of follow-up for the 41 participants were 48.29 ± 11.86 years and 125 months (range 115 to 135 months), respectively. Disease-free survival (DFS) in CD74 negative subjects was better than in CD74 positive patients, but the difference was not statistically significant (p = 0.75). Similarly, HLA-DR negative and HLA-DR positive groups showed no statistically significant differences in terms of DFS (p = 0.81). Conclusion: There were positive but insignificant correlations with increased expression of CD74, decreased expression of HLA-DR, and TILs levels. Further studies involving larger sample sizes may provide more insight into these associations.展开更多
The 8th International Workshop on Human Leucocyte Differentiation Antigens (chaired by Zola H and managed by Swart B) was run over a 4-year period and culminated in a conference in December 2004. Here we review the ac...The 8th International Workshop on Human Leucocyte Differentiation Antigens (chaired by Zola H and managed by Swart B) was run over a 4-year period and culminated in a conference in December 2004. Here we review the achieve- ments of the HLDA Workshops and provide links to information on CD molecules and antibodies against them, including the 93 new CDs assigned in the 8th Workshop. We consider what remains to be achieved (including an estimate of the number of leucocyte surface molecules still to be discovered), and how the field can best move forward.展开更多
1.INTRODUCTION。CD7 is an ideal chimeric antigen receptor(CAR)target for T-cell acute lymphocytic leukemia(T-ALL).Donor-derived CAR-T-cell therapy,as an emerging treatment strategy,shows excellent efficacy in refracto...1.INTRODUCTION。CD7 is an ideal chimeric antigen receptor(CAR)target for T-cell acute lymphocytic leukemia(T-ALL).Donor-derived CAR-T-cell therapy,as an emerging treatment strategy,shows excellent efficacy in refractory/relapsed(r/r)T-ALL,with over 90%of complete remission(CR),brings new promise to improve prognosis and survival quality,and provides more opportunities for following bridging transplantation.1 However,CD7-CAR-T-cell recipients are always immunocompromised for a number of reasons:depletion of healthy T and NK cells;the need for drugs,which are lymphodepleting,prior to CAR-T-cell therapy;a history of hematological malignancies;multiple-lines chemotherapy;and hematopoietic stem-cell transplantation(HSCT).Meanwhile,patients post donor-derived CAR-T-cell therapy are at high risk of graft-versus-host disease(GVHD)considering infusion of allogeneic cell and increase incidence of infection.展开更多
目的比较不同分期的皮肤T细胞淋巴瘤（cutaneous T cell lymphoma，CTCL）患者外周血淋巴细胞表面抗原CD7的缺失情况。方法回顾性分析2006年1月-2010年7月本科收治的41例CTCL患者及9例炎症性皮肤病患者外周血淋巴细胞免疫表型的流式细...目的比较不同分期的皮肤T细胞淋巴瘤（cutaneous T cell lymphoma，CTCL）患者外周血淋巴细胞表面抗原CD7的缺失情况。方法回顾性分析2006年1月-2010年7月本科收治的41例CTCL患者及9例炎症性皮肤病患者外周血淋巴细胞免疫表型的流式细胞检测结果，分析外周血CD7表达。结果41例CTCL患者中，早期（ⅠA～ⅡA）23例和进展期（ⅡB-ⅣB）18例，CD3＋CD7-T细胞比例进展期组与炎症性皮肤病组及早期组比较，均明显升高（P〈0．05）。进展期18例患者中6例CD7缺失（33．33％），早期23例患者中仅1例CD7缺失（4．35％），提示CD7缺失在进展期显著高于早期（P〈0．05）。无外周血累及的25例蕈样内芽肿（mycosis fungoides，MF）患者中有2例CD7缺失，均为进展期，提示进展期MF较早期MF更易出现CD7缺失（P〈0．05）；在进展期MF的CD3＋CD7-T细胞比例均高于早期MF和炎症性皮肤病组（P〈0．05）。结论进展期CTCL和无外周血累及的进展期MF外周血CD3＋CD7-T细胞比例明显高于早期及炎症性皮肤病组，CTCL进展期较早期更容易发生外周血CD7缺失。展开更多
文摘Introduction: Despite the presence of many prognostic and predictive factors, overtreatment remains a major problem in patients with breast cancer. The aim of this study is to investigate the effects of CD74 and HLA-DR expressions on the prognosis of patients who have had a mastectomy for the treatment of breast cancer. Materials and Methods: A retrospective search of medical records was carried out for patients who had surgery for breast cancer at the Department of General Surgery, Akdeniz University School of Medicine, between March 1984 and November 1999. Patients with regular follow-up and necessary data for the study (i.e. patients’ demographics, pathology results, and treatment characteristics) were included in the study. Paraffin blocks of tumor specimens were re-examined with immunohistochemical methods in March 2010 to determine the extent of CD74 and HLA-DR expression and the level of tumor infiltrating lymphocyte (TILs). Results: The mean age and the median duration of follow-up for the 41 participants were 48.29 ± 11.86 years and 125 months (range 115 to 135 months), respectively. Disease-free survival (DFS) in CD74 negative subjects was better than in CD74 positive patients, but the difference was not statistically significant (p = 0.75). Similarly, HLA-DR negative and HLA-DR positive groups showed no statistically significant differences in terms of DFS (p = 0.81). Conclusion: There were positive but insignificant correlations with increased expression of CD74, decreased expression of HLA-DR, and TILs levels. Further studies involving larger sample sizes may provide more insight into these associations.
文摘The 8th International Workshop on Human Leucocyte Differentiation Antigens (chaired by Zola H and managed by Swart B) was run over a 4-year period and culminated in a conference in December 2004. Here we review the achieve- ments of the HLDA Workshops and provide links to information on CD molecules and antibodies against them, including the 93 new CDs assigned in the 8th Workshop. We consider what remains to be achieved (including an estimate of the number of leucocyte surface molecules still to be discovered), and how the field can best move forward.
基金from the clinical trial of CAR-T technique in the Treatment of Malignant Hematological Tumors registered on ClinicalTrials.gov(NCT05618041).
文摘1.INTRODUCTION。CD7 is an ideal chimeric antigen receptor(CAR)target for T-cell acute lymphocytic leukemia(T-ALL).Donor-derived CAR-T-cell therapy,as an emerging treatment strategy,shows excellent efficacy in refractory/relapsed(r/r)T-ALL,with over 90%of complete remission(CR),brings new promise to improve prognosis and survival quality,and provides more opportunities for following bridging transplantation.1 However,CD7-CAR-T-cell recipients are always immunocompromised for a number of reasons:depletion of healthy T and NK cells;the need for drugs,which are lymphodepleting,prior to CAR-T-cell therapy;a history of hematological malignancies;multiple-lines chemotherapy;and hematopoietic stem-cell transplantation(HSCT).Meanwhile,patients post donor-derived CAR-T-cell therapy are at high risk of graft-versus-host disease(GVHD)considering infusion of allogeneic cell and increase incidence of infection.
文摘目的比较不同分期的皮肤T细胞淋巴瘤（cutaneous T cell lymphoma，CTCL）患者外周血淋巴细胞表面抗原CD7的缺失情况。方法回顾性分析2006年1月-2010年7月本科收治的41例CTCL患者及9例炎症性皮肤病患者外周血淋巴细胞免疫表型的流式细胞检测结果，分析外周血CD7表达。结果41例CTCL患者中，早期（ⅠA～ⅡA）23例和进展期（ⅡB-ⅣB）18例，CD3＋CD7-T细胞比例进展期组与炎症性皮肤病组及早期组比较，均明显升高（P〈0．05）。进展期18例患者中6例CD7缺失（33．33％），早期23例患者中仅1例CD7缺失（4．35％），提示CD7缺失在进展期显著高于早期（P〈0．05）。无外周血累及的25例蕈样内芽肿（mycosis fungoides，MF）患者中有2例CD7缺失，均为进展期，提示进展期MF较早期MF更易出现CD7缺失（P〈0．05）；在进展期MF的CD3＋CD7-T细胞比例均高于早期MF和炎症性皮肤病组（P〈0．05）。结论进展期CTCL和无外周血累及的进展期MF外周血CD3＋CD7-T细胞比例明显高于早期及炎症性皮肤病组，CTCL进展期较早期更容易发生外周血CD7缺失。
